-- 
Roche Reports Positive Study of Herceptin in Phase III Study

-- B y   S i m o n e   M e i e r
-- 
2011-10-18T05:07:52Z

-- http://www.bloomberg.com/news/2011-10-18/roche-reports-positive-study-of-herceptin-in-phase-iii-study.html
Roche Holding AG (ROG)  said the phase III
HannaH study demonstrated comparable efficacy of a new
investigational subcutaneous formulation of Herceptin to the
standard intravenous infusion of Herceptin in women with HER2-
positive early breast cancer, according to a statement today.  To contact the editor responsible for this story:
Simone Meier at 
 smeier@bloomberg.net  